Marco Pravetoni, PhD

The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are: 1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose, 2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients, 3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms, 4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2), 5) biosensors for field detection or diagnosis.


PhD in Pharmacology, University of Minnesota, 2008

Scholarly Expertise

  • Vaccines, monoclonal antibodies, immunology, pharmacology, chemical threats, immunoprofiling

Recent Publications

A Membrane-Modulated Centrifugal Microdevice for Enzyme-Linked Immunosorbent Assay-Based Detection of Illicit and Misused Drugs.
(2021 Dec 7)
Anal Chem 93(48): 16213-16221
Dignan LM, Woolf MS, Ross JA, Baehr C, Holstege CP, Pravetoni M, Landers JP

Covalently Loaded Naloxone Nanoparticles as a Long-Acting Medical Countermeasure to Opioid Poisoning.
(2021 Oct 8)
ACS Pharmacol Transl Sci 4(5): 1654-1664
Kassick AJ, Wu M, Luengas D, Ebqa'ai M, Tharika Nirmani LP, Tomycz N, Nelson TL, Pravetoni M, Raleigh MD, Averick S

Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats.
(2021 Nov 2)
Hum Vaccin Immunother 17(11): 4383-4392
Crouse B, Zhang L, Robinson C, Ban Y, Vigliaturo JR, Roy S, Pravetoni M

Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders.
(2021 Aug 1)
J Immunol 207(3): 860-867
Huseby Kelcher AM, Baehr CA, Hamid FA, Hart GT, Pravetoni M

Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge.
(2021 May 13)
NPJ Vaccines 6(1): 69
Stone AE, Scheuermann SE, Haile CN, Cuny GD, Velasquez ML, Linhuber JP, Duddupudi AL, Vigliaturo JR, Pravetoni M, Kosten TA, Kosten TR, Norton EB

Show complete publication list »
Edit Profile